• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Search Results for: patent

Number Of Unique Patent Assertions Declined Over Years, Patexia Finds

17/08/2016 by Intellectual Property Watch 3 Comments

Pedram Sameni of Patexia writes: We recently studied the PTAB data and suggested that although the rise and fall in litigation indirectly affected the rise and fall in IPR challenges, the true driver of IPR challenges is the number of unique patents asserted each year. To learn more, we decided to look at the number of unique patents asserted against different defendants since 2010. We made several interesting discoveries, including the surprising fact that even though the number of cases has been rising, the number of unique patents asserted each year has been declining.

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, English, IP Law, Innovation/ R&D, North America, Patents/Designs/Trade Secrets, Regional Policy

MSF Hearing On Opposition To Pfizer Pneumonia Patent In India

28/07/2016 by Intellectual Property Watch 3 Comments

Médecins Sans Frontières (MSF, Doctors Without Borders) filed a patent opposition in March in India to prevent Pfizer from patenting a pneumonia drug and will defend its position in a hearing tomorrow at the Indian Patent Office.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, Asia/Pacific, English, Health & IP, Human Rights, IP Law, Patents/Designs/Trade Secrets, Regional Policy

US High Court Restores Treble Damages For Patent Infringement

26/07/2016 by Steven Seidenberg for Intellectual Property Watch 3 Comments

Pulse Electronics was guilty of patent infringement. That had been decided long ago. The only remaining issue was how much Pulse must pay for its wrongdoing. The company could be liable for treble damages, provided its infringement was willful. Fortunately for Pulse, willful infringement was almost impossible to prove, thanks to a standard established by the Federal Circuit. Unfortunately for Pulse, its lawsuit reached the US Supreme Court. And in its recent ruling on the case, the high court threw out the Federal Circuit’s standard, making it far easier to prove willful infringement. The decision is likely to have an important impact on patent litigation, the courts, and companies doing business in the US.

Filed Under: Features, IP Policies, Language, Subscribers, Themes, Venues, English, Finance, IP Law, Innovation/ R&D, North America, Patents/Designs/Trade Secrets, Perspectives on the US, Regional Policy

Blockstream’s New Patent Strategy: Trust Us, We Won’t Sue You

21/07/2016 by Intellectual Property Watch 1 Comment

Blockstream, which developed the blockchain technology and bitcoin, has announced a defensive patent strategy. The crux of it: assurance that users of its technology won’t be sued.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, English, Finance, North America, Patents/Designs/Trade Secrets, Regional Policy

WHO Updates Patent Status Info For New Hepatitis C Medicines

20/07/2016 by William New, Intellectual Property Watch 1 Comment

The World Health Organization has issued updated information on the patent status of hepatitis C medicines, including assessments of hurdles for affordable generic versions of latest drugs.

Filed Under: IP Policies, Language, Themes, Venues, English, Health & IP, Innovation/ R&D, Patents/Designs/Trade Secrets, WHO

Patenting By Universities Unhelpful, Paper Says; WIPO Programme To Be Reviewed

19/07/2016 by Catherine Saez, Intellectual Property Watch 2 Comments

A new publication analysing the relationship between intellectual property and access to science explores ways countries have developed to counter the potential barriers created by IP rights, and says patenting by universities is counterproductive.

Filed Under: IP Policies, Language, Themes, Venues, Access to Knowledge/ Education, Development, English, Innovation/ R&D, Patents/Designs/Trade Secrets, Technical Cooperation/ Technology Transfer, WIPO

Gilead’s Use Of Patents For $10B Tax Dodge Could Ignite Move For Policy Change

13/07/2016 by William New, Intellectual Property Watch Leave a Comment

Gilead is the US company whose use of patents to charge $1000 per pill for a hepatitis C medicine in the United States helped make high drug prices a developed country household issue and fodder for elected officials seeking change. Now the company has come under further fire after being found to have moved some US$10 billion overseas to avoid US taxes – even after having received US taxpayer support for its activities – which it orchestrated by moving its patent rights overseas. A new report detailing the company’s tax dodge includes a proposal for a way to clamp down on this type of patent activity.

Filed Under: IP Policies, Language, Themes, Venues, English, Finance, Health & IP, North America, Patents/Designs/Trade Secrets, Regional Policy

Focus On Medicines Patents & Prices Alone May Do More Harm Than Good

12/07/2016 by Intellectual Property Watch Leave a Comment

Populism is in vogue these days and critics of pharmaceutical patents are trying to ride the wave, claiming that undermining patents will dramatically decrease prices but not reduce innovation. Both sides of that claim are flawed, writes Steven Tepp.

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, English, Health & IP, Innovation/ R&D, North America, Patents/Designs/Trade Secrets, Regional Policy, United Nations - other

V4 Countries Launch Visegrad Patent Institute As Region’s First ISA, IPEA

08/07/2016 by Jaroslaw Adamowski for Intellectual Property Watch Leave a Comment

With the aim of strengthening regional cooperation in intellectual property, the four member states of the Visegrad Group, which comprises Poland, Hungary, the Czech Republic and Slovakia, launched the Visegrad Patent Institute (VPI) on 1 July. Applicants will be allowed to communicate with the institutions in their respective mother tongues, and fees for Patent Cooperation Treaty (PCT) applications will be reduced by as much as 40 percent, according to Poland’s Patent Office (UPRP).

Filed Under: IP Policies, Language, Subscribers, Themes, Venues, English, Europe, Innovation/ R&D, Patents/Designs/Trade Secrets, Regional Policy, Technical Cooperation/ Technology Transfer, WIPO

Generic Manufacturing Deals For HIV And Hepatitis C Treatments Signed At Medicines Patent Pool

07/07/2016 by Intellectual Property Watch Leave a Comment

Today the Medicines Patent Pool announced the signing of nine new sub-licensing agreements for the generic manufacturing of key HIV and hepatitis C treatments.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, English, Health & IP, Patents/Designs/Trade Secrets, WHO

  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 347
  • Next Page »
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2026 · Global Policy Reporting